AVI Biopharma, Inc. (AVII) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Join SI Premium – FREE
AVI Biopharma, Inc. (NASDAQ: AVII) reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $15.5 million versus the consensus estimate of $11.65 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
